New HIV ‘vaccine’ could cost as little as $40 per year for patients: Research
ANKARA: A new “vaccine-like” HIV drug could cost as little as $40, according to new research.
Lenacapavir, an antiretroviral drug developed by US pharmaceutical company, Gilead, currently costs $42,250 for the first year for patients in the US, Franc…